Feb 6 (Reuters) - The U.S. Food and Drug Administration on Friday said it plans to restrict GLP-1 ingredients used in non-approved compounded drugs that companies such as Hims & Hers HIMS.N and other compounding pharmacies have been marketing as alternatives to authorized treatments, citing concerns over quality, safety and potential violations of federal law.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Alan Barona)
((siddhi.mahatole@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.